KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Buildings (2016 - 2024)

Historic Buildings for Gilead Sciences (GILD) over the last 15 years, with Q4 2024 value amounting to $4.5 billion.

  • Gilead Sciences' Buildings rose 487.52% to $4.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 billion, marking a year-over-year increase of 487.52%. This contributed to the annual value of $4.5 billion for FY2024, which is 487.52% up from last year.
  • As of Q4 2024, Gilead Sciences' Buildings stood at $4.5 billion, which was up 487.52% from $4.3 billion recorded in Q4 2023.
  • In the past 5 years, Gilead Sciences' Buildings ranged from a high of $4.5 billion in Q4 2024 and a low of $3.7 billion during Q4 2020
  • For the 5-year period, Gilead Sciences' Buildings averaged around $4.1 billion, with its median value being $4.3 billion (2023).
  • Its Buildings has fluctuated over the past 5 years, first surged by 1570.9% in 2022, then tumbled by 141.23% in 2023.
  • Gilead Sciences' Buildings (Quarter) stood at $3.7 billion in 2020, then grew by 3.15% to $3.8 billion in 2021, then grew by 15.71% to $4.4 billion in 2022, then decreased by 1.41% to $4.3 billion in 2023, then rose by 4.88% to $4.5 billion in 2024.
  • Its Buildings stands at $4.5 billion for Q4 2024, versus $4.3 billion for Q4 2023 and $4.4 billion for Q4 2022.